APA (7th ed.) Citation

GJ, C., RMGJ, H., K, F., AL, F., H, E., AD, G., . . . RG, W. (2024). Implications of subclinical tuberculosis for vaccine trial design and global effect. The Lancet. Microbe, 5(10), 100895. https://doi.org/10.1016/S2666-5247(24)00127-7

Chicago Style (17th ed.) Citation

GJ, Churchyard, et al. "Implications of Subclinical Tuberculosis for Vaccine Trial Design and Global Effect." The Lancet. Microbe 5, no. 10 (2024): 100895. https://doi.org/10.1016/S2666-5247(24)00127-7.

MLA (9th ed.) Citation

GJ, Churchyard, et al. "Implications of Subclinical Tuberculosis for Vaccine Trial Design and Global Effect." The Lancet. Microbe, vol. 5, no. 10, 2024, p. 100895, https://doi.org/10.1016/S2666-5247(24)00127-7.